1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CACancer J Clin. 2023;73(1):17.PMID: 36633525
2. Hernández JA, Land KJ, McKenna RW. Leukemias, myeloma, and otherlymphoreticular neoplasms. Cancer. 1995;75(1 Suppl):381.PMID: 8001009
3. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C,et al. Global, Regional, and National Cancer Incidence, Mortality, Years ofLife Lost, Years Lived With Disability, and Disability-Adjusted Life-yearsfor 32 Cancer Groups, 1990 to 2015: A Systematic Analysis forthe GlobalBurden of disease study. JAMA Oncol 2017; 3:524.
4. Yamamoto JF, Goodman MT. Patterns of leukemia incidence in theUnited States by subtype and demographic characteristics, 1997-2002.Cancer Causes Control 2008; 19:379.
5. Miranda-Filho A, Piñeros M, Ferlay J, et al. Epidemiological patterns ofleukaemia in 184 countries: a population-based study. Lancet Haematol2018;5(1):e14-e24.
6. Yang S, Varghese AM, Sood N, et al. Ethnic and geographic diversity ofchronic lymphocytic leukaemia. Leukemia 2021;35(2):433-439.
7. Hallek M, Cheson BD, Catovsky D, et al. İw CLL guidelines for diagnosis,indications for treatment, response assessment, and supportivemanagement of CLL. Blood. 2018;21;131(25):2745-2760
8. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chroniclymphocytic leukemia. Blood. 1975;46(2):219-234.
9. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classificationof chronic lymphocytic leukemia derived from a multivariate survivalanalysis. Cancer. 1981;48(1):198-206.
10. Lazarian G, Munger M, Quinquenel A, et al. Clinical and biologicalcharacteristics of leukemia cutis in chronic lymphocytic leukemia: Astudy of the French innovative leukemia organization (FILO). Am JHematol. 2021;96(9):E353-E356.
11. Strati P, Uhm JH, Kaufmann TJ, et al. Prevalence and characteristics ofcentral nervous system involvement by chronic lymphocytic leukemia.Haematologica. 2016;101(4):458-65.
12. Poitou-Verkinder AL, Francois A, Drieux F, et al. The spectrum ofkidney pathology in B-cell chronic lymphocytic leukemia / smalllymphocytic lymphoma: a 25-year multicenter experience. PLoSOne2015;10(3):e0119156
13. Baer MR, Stein RS, Dessypris EN. Chronic lymphocytic leukemiawith hyperleukocytosis. The hyperviscosity syndrome. Cancer.1985;56(12):2865-2869
14. Diehl LF, Ketchum LH. Auto immune disease and chronic lymphocyticleukemia: auto immune hemolytic anemia, püre red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol. 1998;25(1):80-97.
15. Parikh SA, Leis JF, Chaffee KG, et al. Hypogammaglobulinemia innewly diagnosed chronic lymphocytic leukemia: Natural history, clinicalcorrelates, and outcomes. Cancer. 2015;121(17):2883-2891
16. Nowakowski GS, Hoyer JD, Shanafelt TD, et al. Using smudge cells onroutine blood smears to predict clinical outcome in chronic lymphocyticleukemia: a universally-available prognostic test. Mayo ClinProc.2007;82(4):449-453
17. Rawstron AC, Villamor N, Ritgen M, et al. International standardizedapproach for flow cytometric residual disease monitoring in chroniclymphocytic leukaemia. Leukemia. 2007;21(5):956-964.
18. Ben-Ezra J, Burke JS, Swartz WG, et al. Small lymphocytic lymphoma: aclinicopathologic analysis of 268 cases. Blood. 1989;73(2):579-587
19. Thomas R, Ribeiro I, Shepherd P, et al. Spontaneous clinical regression inchronic lymphocytic leukaemia. Br J Haematol. 2002;116(2):341-345
20. Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensiveprognostic index for patients with chronic lymphocytic leukemia. Blood.2014;124(1):49-62
21. Moreno C, Hodgson K, Ferrer G, et al. Auto immune cytopenia in chroniclymphocytic leukemia: prevalence, clinical associations, and prognosticsignificance. Blood. 2010;116(23):4771-4776.
22. Zenz T, Vollmer D, Trbusek M, et al. European Research Initiative onCLL (ERIC). TP53 mutation profile in chronic lymphocytic leukemia:evidence for a disease specific profile from a comprehensive analysis of268 mutations. Leukemia. 2010;24(12):2072-2079.
23. International CLL-IPI working group. An international prognostic indexfor patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790.
24. Montserrat E, Vinolas N, Reverter JC, et al. Chronic lymphocytic leukemiain early stage "smoldering" and "active" forms in chronic lymphocyticleukemia. In: Scientific Advances and Clinical Developments, ChestonBD (Ed), Marcel Decker, New York 1993. p.281.
25. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. JNatlCancerInst. 1999;91(10):861-868
26. Morrison WH, Hoppe RT, Weiss LM, et al. Small lymphocyticlymphoma. J ClinOncol. 1989;7(5):598-606.
27. Moreno C, Greil R, Demirkan F et al. Ibrutinib plus obinutuzumabversus chlorambucil plus obinutuzumab in first-line treatment ofchronic lymphocytic leukaemia (iLLUMINATE): a multicentre,randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43-56.
28. Shanafelt TD, Wang XV, Kay NE et al. Ibrutinib-rituximab orchemoimmunotherapy for chronic lymphocytic leukemia. N Engl JMed. 2019;381:432-43
29. Sharman JP, Egyed M, Jurczak W et al. Acalabrutinib with or withoutobinutuzumab versus chlorambucil and obinutuzumab for treatmentnaïve chronic lymphocytic leukemia (ELEVATE TN): a randomised,controlled, phase 3 trial. Lancet. 2020;395(10232):1278-1291.
30. Weirda WG et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-linetreatment of chronic lymphocytic leukemia (CLL)/smalllymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) resultsfromthe MRD cohort of the Phase 2 CAPTIVATE study. AmericanSociety of Hematology Annual Meeting 2020: Oral Presentation.